Squamous Cell Carcinoma News and Research

RSS

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.

New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer

A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus-related head and neck cancer.

24 Sep 2018

Researchers use CRISPR screen to reveal new targets in squamous cell carcinomas

A little p63 goes a long way in embryonic development - and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs.

18 Sep 2018

Machine learning program could distinguish between two lung cancer types

A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

17 Sep 2018

Immune-related enzymes cause aggressive skin cancer in patients with Butterfly Syndrome

Patients with a rare skin disease, commonly called Butterfly Syndrome, that causes chronic blistering and extensive scarring also develop an aggressive and fatal form of cancer early in life.

28 Aug 2018

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Forbius announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas.

25 Aug 2018

Discovery could lead to new targeted treatment for people with lung cancer

Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.

22 Aug 2018

Researchers compare existing approaches for automating diagnostic procedures of skin lesions

The three prevalent skin cancers, according to the literature are melanoma, basal cell carcinoma and squamous cell carcinoma.

15 Aug 2018

Childhood trauma associated with anxiety and depression in adults with head and neck cancer

Among individuals with head and neck cancer, those who experienced childhood trauma were more likely to have advanced cancer, to have higher alcohol consumption, and to experience symptoms of anxiety and depression.

6 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Cancer patients receiving anti-PD-1 therapies may experience delayed skin reactions

Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay – sometimes even after treatment has concluded.

19 Jul 2018

Allergic responses may help protect the skin against cancer, research suggests

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings.

18 Jul 2018

Testosterone effective at fighting cachexia in cancer patients, research shows

Many cancer patients suffer from a loss of body mass known as cachexia. Approximately 20 percent of cancer-related deaths are attributed to the syndrome of cachexia, which in cancer patients is often characterized by a rapid and/or severe loss of fat and skeletal muscle.

13 Jul 2018

Sylvester dermatologist uses HPV vaccine to treat patient with squamous cell tumors

Squamous cell carcinoma is the second-most-common form of skin cancer. Evidence suggests the human papilloma virus plays a role in the development of some types of this skin cancer.

3 Jul 2018

Researchers develop new methods for studying evolution of cancer treatment resistance

New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center.

3 Jul 2018

Review discusses complexity of immune-suppressive mechanisms in tumor milieu of cancers

Cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression.

29 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Study identifies new biomarker for early lung cancer diagnosis

High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer.

8 May 2018

New data supports clinical use of DecisionDx-Melanoma test to inform SLNB options

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma test to inform sentinel lymph node biopsy (SLNB) recommendations.

7 May 2018